Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?

Vertex Pharmaceuticals (NASDAQ: VRTX) has performed well in 2026. Its shares are up 13% year-to-date, while the S&P 500 is up 10%. However, after reaching $560.25 per share earlier this year, the company has dropped 8% from that 52-week high. Should investors take advantage of this opportunity to buy the stock on the dip?

Vertex Pharmaceuticals' second-quarter results were strong. The company's revenue increased by 12% year over year to $3.33 billion, while its earnings per share climbed 8% year over year to $4.31. Vertex increased its full-year revenue guidance to $13.1 billion to $13.2 billion, up from its previous range of $12.95 billion to $13.1 billion. There are several things investors should pay attention to over the next year. Here are three of them.

Image source: The Motley Fool.

Continue reading